Catalyst Wire Dossier Catalyst Wire Dossier

Tapentadol ER (CG5503)

tapentadol · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tapentadol ER (CG5503), covering 2010-07-23 to 2010-07-23. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain [Phase 3]

See pricing